WEDNESDAY, SEPTEMBER 29, 2021
GRAND BALLROOM — RITZ CARLTON

1:00 pm  WELCOME
Allen Ho, MD, President

INTERESTING RETINAL CASES AND VIDEO PRESENTATIONS
MODERATORS: Anita Agarwal, MD and Mark Johnson, MD

1:05  Nothing Was Seen
Carol Shields, MD

1:10  Planned Preterm Delivery and Treatment of Osteoporosis-Pseudoglioma Syndrome
Robert Sisk, MD

1:15  Snowflake Maculopathy
Mark Johnson, MD

1:20  "I Was Just Tending to My Orchids."
Jaclyn Kovach, MD; Anita Agarwal

1:25  I Can’t Jump and I’m Losing My Vision!
Benjamin Kim, MD

1:30  Third Time’s the Charm
Lihteh Wu, MD

1:35  What Are Those Dots?
Rukhsana Mirza, MD

1:40  Occam’s Razor or Hickam’s Dictum: Mystery Case
Jesse Jung, MD

1:45  A Spleendid Case!—An IRD with Other Findings
Kimberly Stepien, MD

1:50  Tying the Knots with a wRAP
Aaron Nagiel, MD, PhD

1:55  Maculopathy in a 40-Year-Old Woman
Anita Agarwal, MD

2:00  One Step at a Time
Manjot Gill, MD

2:05  Intraocular Solitary Fibrous Tumor/Hemangiopericytoma with Extrascleral Extension
Scott Oliver, MD

2:10  It’s in the X
Audina Berrocal, MD

VIDEO PRESENTATIONS

2:15  Minimal Gas Vitrectomy with Scleral Buckle to Minimize Retinal Displacement in Rhegmatogenous Retinal Detachment with Inferior Breaks
Rajeev Muni, MD, MSc, FRCS

2:20  Surgical Management of a Total Tractional Retinal Detachment in a 2-Month-Old Infant with Severe Vitreoretinopathy and a Mutation in CAPN5
Lejla Vajzovic, MD

2:25  Vitreo-Retinal Illumination in UGH Syndrome and Dislocated IOLs
Maria Berrocal, MD

2:30  Superior Wide-Base Internal Limiting Membrane Flap Transposition (SWIFT) for Macular Holes
Homayoun Tabandeh, MD, MS
Open Sky Full of Air: Unexpected Retinal Detachment Repair in a Post-Trauma Eye
Christina Weng, MD, MBA

Intraoperative Microscope-Integrated Optical Coherence Tomograph Imaging During Fine Needle Aspiration Biopsy of Uveal Melanoma
Colleen Cebulla, MD

IOCB Removal
Glenn Yiu, MD, PhD

A Sudden Loss of Pressure
Andre Witkin, MD

REFRESHMENT BREAK

WEDNESDAY, SEPTEMBER 29, 2021
GRAND BALLROOM — RITZ CARLTON

DIABETIC RETINOPATHY
MODERATORS: Lloyd Aiello, MD and Diana Do, MD

3:20 pm Loss to Follow Up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and/or PRP in the United States
Rahul Khurana, MD

3:25 Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution in Patients Treated with Ranibizumab: A Meta-Analysis of 5 Clinical Trials
Katherine Talcott, MD

3:29 An EHR-Based Predictive Model to Understand Lost-to-Follow-Up Risk in Patients with Diabetic Retinopathy
Durga Borkar, MD

3:33 Discussion of above 3 papers

3:39 A Randomized Clinical Trial of Intravitreal Aflibercept Versus Vitrectomy with Panretinal Photocoagulation for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy: DRCR Retina Network Protocol AB
John Wells, MD

3:45 Discussion

3:48 A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Hani Salehi-Had, MD

3:54 pm Discussion

3:57 Decreased Vision Improvement in DME Eyes with Longer Duration Larger Amounts of Excess Edema: A Post-hoc Analysis of Protocol T
Baruch Kuppermann, MD, PhD

4:01 Five-Year Analysis of Ultra-responders to Ranibizumab for Proliferative Diabetic Retinopathy in DRCR.net Protocol S
Allen Chiang, MD

4:05 Discussion of above 2 papers

4:09 Complement Activation in the Aqueous of Patients with Proliferative Diabetic Retinopathy
Jesse Smith, MD

4:13 Discussion

4:15 Risk Factors Associated with Progression to Diabetic Macular Edema and/or Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy: A Post-hoc Analysis of the PANORAMA Study
Roger Goldberg, MD, MBA

4:19 Impact of Delayed Treatment in Diabetic Retinal Disease: Experiences from VISTA/VIVID and PANORAMA
Dilsher Dhoot, MD
4:23 Visual Impact of Vision Threatening Complications and Center-Involved Diabetic Macular Edema in Patients with Non-proliferative Diabetic Retinopathy: Results from the PANORAMA Trial
Diana Do, MD

4:27 Discussion of above 3 papers

4:33 The Association of Retinal Ischemia with Neovascular Glaucoma in Proliferative Diabetic Retinopathy Using Widefield Swept-Source Optical Coherence Tomography Angiography
John Miller, MD

4:37 The Impact of Image Processing Algorithms on Quantitative Optical Coherence Tomography Angiography Metrics in Diabetic Retinopathy
Jay Wang, MD

4:41 Accuracy of Detecting Referable Diabetic Retinopathy by Clinical Examination, Vitreoretinal Specialist Graders and a Reading Center Against a Reference Standard Validated Against Clinical Outcome
James Folk, MD

4:46 Discussion of above 3 papers

4:53 Adjourn

6:00 WELCOMING RECEPTION — MUSEUM OF CONTEMPORARY ART
THURSDAY, SEPTEMBER 30, 2021
GRAND BALLROOM — RITZ CARLTON

7:30 am  WELCOME | ANNOUNCEMENTS

RETINAL SURGERY
MODERATORS: David Zacks, MD, PhD and Julia Haller, MD

7:32  Stabilization Versus Progression of Subclinical Retinal Detachments Treated with Barrier Laser Photocoagulation
Uday Desai, MD

7:37  Laser Treatment After Minimized Eye Movement (LTMEM) for Repair of Retinal Detachment
Greg Kokame, MD, MMM

7:43  Discussion of above 2 papers

7:49  Outer Retinal Folds Following Pars Plana Vitrectomy Versus Pneumatic Retinopexy for Retinal Detachment Repair: Post-hoc Analysis from PIVOT
Rajeev Muni, MD, MSc, FRCSC

7:55  Discussion

7:58  Full-Thickness Macular Holes After Surgical Repair of Primary Rhegmatogenous Retinal Detachments: Incidence, Clinical Characteristics, and Outcomes
Omesh Gupta, MD, MBA

8:02  Discussion

8:04  Deletion of High-Mobility Group Box 1 (HMGB1) in Rods Reduces Autophagy Activation After Retinal Detachment
David Zacks, MD, PhD

8:09  Discussion

8:11  A Randomized Clinical Trial of Pneumatic Vitreolysis for Vitreomacular Traction: DRCR Retina Network Protocol AG
Clement Chan, MD, FACS

8:17  A Single-Arm Study of Pneumatic Vitreolysis for Macular Hole: DRCR Retina Network Protocol AH
Calvin Mein, MS

8:23  Discussion of above 2 papers

8:29  SURGICAL DISCUSSION

DRY AGE-RELATED MACULAR DEGENERATION
MODERATORS: Jeffrey Heier, MD and Carl Regillo, MD

8:44  Plasma Metabolomic Profiles Associated with Delayed Dark-Adaptation in Age-Related Macular Degeneration
Deeba Husain, MD

8:48  Defining the Retinal Transcriptomic Changes Secondary to Diet-Induced Gut-Dysbiosis
Dimitra Skondra, MD

8:52  Discussion of above 2 papers

8:56 am  Regression of Drusen or Vitelliform Material Heralding Geographic Atrophy: Correlation between Clinical Observations and Basic Science
Mark Johnson, MD
Factors Associated with Loss to Follow-Up in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration in the IRIS® Registry
Theodore Leng, MD, MS

Age-Related Macular Degeneration and Cardiovascular Disease
Theodore Smith, MD, PhD

Low-Luminance Visual Acuity and the Association of Ellipsoid Zone Integrity in Dry Age-Related Macular Degeneration Patients Treated with Subcutaneous Elamipretide: Post-hoc Analysis of the Phase 1 ReCLAIM-1 Study
Dante Pieramici, MD

Interim Results from a First-in-Human Phase I/II Gene Therapy Study (FOCUS) of GT005, an Investigational AAV2 Vector Encoding Complement Factor I, in Patients with Geographic Atrophy
Szilard Kiss, MD

Role of C1q Inhibition in the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
David Lally, MD

Intravitreal RBM-007, a Novel Anti-angiogenic and Anti-scarring Agent, in Recalcitrant Exudative Age-Related Macular Degeneration Patients: Interim Safety Update on the Phase 2 TOFU and the RAMEN Extension Study
Raj Maturi, MD

Phase 1/2a Clinical Trial of Transplanted Allogeneic Retinal Pigmented Epithelium (RPE, OpRegen) Cells in Advanced Dry Age-Related Macular Degeneration (AMD): Interim Result
Christopher Riemann, MD

Efficacy of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from Two Phase 3 Trials
Jeffrey Heier, MD

Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from Two Phase 3 Trials
Charles Wykoff, MD, PhD

Eighteen-Month Results from GATHER1 Clinical Trial: Avacincaptad Pegol, a Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth
Carl Regillo, MD

Efficacy of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from Two Phase 3 Trials
Jeffrey Heier, MD

Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from Two Phase 3 Trials
Charles Wykoff, MD, PhD

Panel discussion of above 2 papers

REFRESHMENT BREAK/EXHIBITS
MODERATORS: Allen Ho, MD and David Brown, MD

11:10 am Longer Term Visual Outcomes and Anti-VEGF Therapy Intensity in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema and Retina Vein Occlusion Related Macular Edema: A Real World Analysis of 130,247 Patient Eyes
Thomas Ciulla, MD, MBA

11:14 Discussion

11:16 Risk Factors for Acute Elevated Intraocular Pressure After Intra-vitreal Anti-VEGF Injections
Tom Chang, MD

11:19 Discussion

11:20 Efficacy, Safety, and Durability of Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): 48-Week Results from the Phase 3 TENAYA and LUCERNE Trials
Philip Ferrone, MD

11:26 Discussion

11:29 Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration (nAMD)
Nathan Steinle, MD

11:32 Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients with Neovascular Age-Related Macular Degeneration (nAMD) Treated with Anti-VEGFs in VIEW Trials
Chirag Shah, MD, MPH

11:35 Does Central Retinal Thickness Fluctuation Really Impact Visual Acuity in Neovascular Age-Related Macular Degeneration (nAMD)? A Post-hoc Analysis of the CEDAR/SEQUOIA Phase 3 Trials
Jeremy Wolfe, MD, MS

11:38 Discussion of above 3 papers

11:41 Long-Term Efficacy Outcomes with Brolucizumab vs Aflibercept Treatment in Patients with Early Residual Fluid Presence in Neovascular Age-Related Macular Degeneration (nAMD): Post-hoc Analysis of Pooled Data from HAWK & HARRIER Studies
Michael Singer, MD

11:44 Potential for Treatment Interval Extension in nAMD with Brolucizumab—An Analysis of HAWK and HARRIER 48-Week Data
Seenu Hariprasad, MD

11:47 Comparing Maximum Thickness of Pigment Epithelial Detachments and Sub-retinal Pigment Epithelium Fluid in Patients Treated with Brolucizumab Versus Aflibercept in the HAWK & HARRIER Studies
David Wong, MD

11:50 Discussion of above 3 papers

11:53 FELLOWSHIP RESEARCH AWARD
INTRODUCTION: Prithvi Mruthyunjaya, MD, MHS
Geographic Access Disparities to Retinopathy of Prematurity Treatment Centers in the United States
Rebecca Soares, MD

12:08 pm RETINA RESEARCH FOUNDATION AWARD/CHARLES L. SCHEPENS LECTURE
INTRODUCTION: Andrew Schachat, MD
Uveitis Management: What Have We Learned from Clinical Trials?
Douglas Jabs, MD, MBA

12:38 LUNCH

1:23 DESSERT AND POSTER SESSION
ARTIFICIAL INTELLIGENCE

MODERATORS: Jennifer Lim, MD and Justis Ehlers, MD

2:08 pm Single-Exam Risk Prediction of Severe Retinopathy of Prematurity Using Artificial Intelligence
Peter Campbell, MD, MPH

2:14 Discussion

2:17 A Deep Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on SD-Optical Coherence Tomography: Opening the Black Box of AI for GA Prediction
Eleonora Lad, MD, PhD

2:23 Discussion

2:26 Artificial Intelligence Using Differential Artery-Vein Classification in Optical Coherence Tomography Angiopathy Improves Detection and Staging of Sickle Cell Retinopathy
Jennifer Lim, MD

2:31 Sputtering Pipes and Choking Streams — Quantification of Intermittent Retinal Capillary Perfusion in Sickle Cell Disease Using Sequential Optical Coherence Tomography Angiography
Richard Rosen, MD, ScD

2:35 Discussion of above 2 papers

2:39 Automated Image Quality Assessment for Spectral-Domain Optical Coherence Tomography: Utilization of the Segmentation Confidence Score and Intrinsic Image Features
Justis Ehlers, MD

2:44 Self-Supervised Feature Learning and Phenotyping for Assessing Age-Related Macular Degeneration Using Retinal Fundus Images
Glenn Yiu, MD, PhD

2:49 Evaluation of an Artificial Intelligence System for Retinopathy of Prematurity Screening in Nepal and Mongolia
Paul Chan, MD

Rogerio Garcia Nespolo, MSc

3:00 Extended discussion of above 4 papers and other questions

3:14 Vitreous Cytokine Profile in Central Retinal Vein Occlusion in the ORION Study
Victor Gonzalez, MD

3:18 Discussion

3:20 REFRESHMENT BREAK/EXHIBITS

3:50 LATE BREAKING PRESENTATION
Clinically Relevant Outcomes from DRCR Retina Network Protocol AB: Intravitreal Aflibercept Versus Vitrectomy with Panretinal Photocoagulation for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy
Andrew Antoszyk, MD

3:55 Discussion

3:58 pm LATE BREAKING PRESENTATION
Completion of Scheduled Follow-Up Visits After Intravitreal Ranibizumab Injections Among Participants in a Clinical Trial for Proliferative Diabetic Retinopathy
Maureen Maguire, MD

4:03 Discussion

4:06 Tokyo 2020 Paralympic Gold Medalist and World Record Holder Gia Pergolini and Through Gia’s Eye Foundation
4:36  PANEL: The Art of Innovation  
**MODERATOR:** Emmett Cunningham, MD, PhD, MPH  
**PANELISTS:** Eugene de Juan, MD, Darius Moshfeghi, MD, Ron Weiss, MD, David Zacks, MD, PhD

5:06  ADJOURN

6:00 – 8:00  **BEFORE RECEPTION — THE CAFÉ, TAROLI ROOFTOP BAR at THE RITZ-CARLTON**

10:00 – Midnight  **BEFORE RECEPTION — THE CAFÉ, TAROLI ROOFTOP BAR at THE RITZ-CARLTON**
FRIDAY, OCTOBER 1, 2021
GRAND BALLROOM — RITZ CARLTON

7:30 am  WELCOME | ANNOUNCEMENTS

TUMORS
MODERATORS: Timothy Murray, MD and Ivana Kim, MD

7:32  Design, Methods, and Rationale for the Collaborative Ocular Oncology Group 2 (COOG2) Study
Amy Schefler, MD, FACS

7:36  Discussion

7:38  Ten-Year Outcomes of Uveal Melanoma Based on The Cancer Genome Atlas (TCGA) Classification in 1001 Cases
Carol Shields, MD

7:44  Discussion

7:47  Ultra-Widefield Spectral-Domain Optical Coherence Tomography Imaging of Peripheral Tumors: Impact on Diagnosis and Clinical Care
Timothy Murray, MD, MBA

7:53  Discussion

7:56  Ocular Tumor Regression Patterns in Patients with Metastatic Uveal Melanoma
Ivana Kim, MD

8:01  Does Gene Expression Profile (GEP) and Preferentially Expressed Melanoma Antigen (PRAME) Predict Metastatic Risk in All Uveal Melanoma, Including Small Tumors and Iris Melanoma?
Scott Oliver, MD

8:06  Discussion of above 2 papers

8:10  Vitreous Proteomics by Mass Spectrometry Correlates with Gene Expression Profile of Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS

8:16  Discussion

8:19  Next Generation Sequencing of Vitreous Liquid Biopsies Reveals Diagnostic Biomarkers and Targetable Alterations in Vitreoretinal Lymphoma
Rajesh Rao, MD

8:24 am  Discussion

8:26  What Happens to Plasma cfDNA (RB1) After Enucleation?
Jasmine Francis, MD

8:31  Discussion

8:33  Multimodal Imaging in the Diagnosis of Exophytic Juxtapapillary Retinal Capillary Hemangioblastoma
Victor Villegas, MD

8:37  Discussion

MACULAR SURGERY
MODERATORS: Carl Awh, MD and Maria Berrocal, MD

8:39  Real-Time In Vivo Assessment of Retinal Reattachment in Humans Using Swept-Source Optical Coherence Tomography
Wei Wei Lee, MD

8:44  Assessment of Real-Time Microscope Integrated Optical Coherence Tomography Volumetric (4D) and B-scan Images Integrated in a 3D Surgical Platform During Human Vitreoretinal Surgery
Henry Feng, MD
8:48 Discussion of above 2 papers
8:52 Visual and Anatomic Outcomes for Superior Wide-Base Internal Limiting Membrane Flap Transposition (SWIFT)
Homayoun Tabandeh, MD
8:56 Discussion
8:58 Injection Drug Use-Associated Endogenous Endophthalmitis Compared with Other Causes of Endogenous Endophthalmitis
Margaret Greven, MD
9:02 Discussion
9:04 Factors Associated with Good Visual Acuity Outcomes After Retinectomy in Eyes with Proliferative Vitreoretinopathy
Jason Hsu, MD
9:08 Discussion
9:10 Peel Induced Maculopathy (PIM) Following Membrane Peeling Using a Micro-vacuum Pick (MVP) Versus Forceps
Carl Awh, MD
9:14 Extended discussion for this paper and additional questions
9:34 RAYMOND R. MARGHERIO AWARD
INTRODUCTION: Prithvi Mruthyunjaya, MD, MHS
Pharmacologic Activation of Autophagy without Direct mTOR Inhibition as a Therapeutic Strategy for Treating Dry Macular Degeneration
Jason Miller, MD, PhD
9:49 J. DONALD M. GASS AWARD
INTRODUCTION: David Sarraf, MD
How Understanding the Histologic Basis of Retinal Imaging Findings in Age-Related Macular Degeneration Can Improve Patient Outcomes and Future Implications
Bailey Freund, MD
10:19 REFRESHMENT BREAK/EXHIBITS
GENETIC DISEASES, DYSTROPHIES & DEGENERATIONS
MODERATORS: Ninel Grigori, MD and Lejla Vajzovic, MD
10:49 Perifoveal Chorioretinal Atrophy Following Subretinal Voretigene Neparvovec-rzyl for RPE65-mediated Leber Congenital Amaurosis
Aaron Nagiel, MD, PhD
10:54 Does Patient Age, Baseline Visual Acuity, and Intraoperative Foveal Detachment Affect Clinical Outcomes After Voretigene Neparvovec-rzyl Administration for RPE65-Associated Inherited Retinal Disease?
Ninel Gregori, MD
10:59 Discussion of above 2 papers
11:03 Optogenetic Vision Restoration in ABCA4 Mutation Retinal Degeneration Patients
Sai Chavala, MD
11:08 Partial Recovery of Visual Function in a Blind Patient After Optogenetic Therapy for Non-syndromic Retinitis Pigmentosa
José-Alain Sahel, MD
11:12 Discussion of above 2 papers
11:16 Using a Commercial Intraoperative Optical Coherence Tomography System to Measure Transvitreal Subretinal Injection Volume
Intraoperative Bleb Behavior in Subretinal Gene Transfer for Inherited Retinal Diseases

Discussion of above 2 papers

Aggressive Approach to Intraocular Hypertension and/or Glaucoma in Retinitis Pigmentosa

Discussion

ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-related Stargardt Disease: Results of a Phase 2 Placebo-Controlled Clinical Trial (TEASE study)

Announcement of Retina Society Research and Education Fund Award Winners: Dr Susanna Park and Dr Cagri Besirli

Retina Society Annual Business Meeting (members only)

LUNCH

DESSERT AND POSTER SESSION

WET AGE-RELATED MACULAR DEGENERATION II

Moderators: Peter Kaiser, MD and Robert Avery, MD

The Archway Phase 3 Trial of the Port Delivery System with Ranibizumab (PDS) for Neovascular Age-Related Macular Degeneration (nAMD): Updated Safety and Efficacy Results

Outcomes in Neovascular Age-Related Macular Degeneration Patients Presenting with Poor Visual Acuity

Characterization of Retinal AI-Based Fluid Volume Trajectories from Self-Imaging with a Home Optical Coherence Tomography System

Thermal Laser Treatment of Polypoidal Lesions in Patients with Polypoidal Choroidal Vasculopathy: A Case Series

Columbus-Age-Related Macular Degeneration: Efficacy and Safety of FYB201, a Proposed Biosimilar to Ranibizumab, in Neovascular Age-Related Macular Degeneration (nAMD)

Subretinal Delivery of RGX-314 for Neovascular Age-Related Macular Degeneration: End of Study Phase I/IIa Results

Suprachoroidal Delivery of RGX-314 for Neovascular Age-Related Macular Degeneration: Initial Results from the Phase II AAVIATE® Study
Comparison of Suprachoroidal and Intravitreal Injection Flow Mechanics Analyzed via Multimodal Imaging
Dennis Marcus, MD

Discussion of above 3 papers

ADVM-022 Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration — Phase 1 OPTIC Study
Arshad Khanani, MD

Discussion

Comparing Endophthalmitis After Cataract Surgery and Endophthalmitis After Intravitreal Injection
Daniel Roth, MD

Discussion

REFRESHMENT BREAK/EXHIBITS

IMAGING
MEDITORS: Cynthia Toth, MD and David Sarraf, MD

Feasibility and Clinical Utility of Ultra-Widefield Navigated Swept-Source Optical Coherence Tomography Imaging
Kyle Kovacs, MD

Discussion

Prospective Longitudinal Study: Fluid Quantification from Daily Self-Imaging with Home Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration (NV-AMD)
Nancy Holekamp, MD

Discussion

Epivascular Glia: Identification and Characterization Using En Face Optical Coherence Tomography Analysis
David Sarraf, MD

Discussion

Peripapillary Vitreoretinal Interface (PVI) Staging and Retina Surgery Implications
David Brown, MD

Discussion

Volumetric Analysis of Macular Holes
Thanos Papakostas, MD

Discussion

Changes in Utilization Patterns of Retinal Procedures and Services Following Private Equity Acquisition
Christina Weng, MD, MBA

Discussion

LATE BREAKING PRESENTATION
A Multicenter, Non-interventional, Observational, Post-Authorization Safety Study of Patients Treated with Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at One Year
Aaron Nagiel, MD, PhD

Discussion

LATE BREAKING PRESENTATION
Progression Analysis of Drusen and Intermediate Age-Related Macular Degeneration Subjects: A Post-hoc Analysis of 18-Month GATHER1 Data
SriniVas Sadda, MD

Discussion

ADJOURN
7:00 – 11:00  RECEPTION AND GALA BANQUET — GRAND BALLROOM
8:00 am

**WELCOME | ANNOUNCEMENTS**

**INFLAMMATION**

**MODERATORS:** Steven Yeh, MD and Thomas Albini, MD

8:02

**Retinopathy and Systemic Disease Morbidity in Severe COVID-19**

Steven Yeh, MD

8:07

**Effects of Delay in Care on Short- and Long-Term Visual Acuity Outcomes in Patients Requiring Intravitreal Injections**

Aleksandra Rachitskaya, MD

8:11

**COVID-19 Pandemic Lockdown Effect on Outcomes and Practice Patterns for Primary Retinal Detachment: A Multicenter Experience in North America**

Jesse Jung, MD

8:15

**Retinal Vein Occlusions Associated with COVID-19 Infection**

Avni Finn, MD, MBA

8:19

Discussion of above 4 papers

8:27

**Bacterial Dispersion Associated with Various Patient Face Mask Designs During Simulated Intravitreal Injections**

Ajay Kuriyan, MD, MS

8:31

**The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal anti-VEGF Injections During the COVID-19 Pandemic**

Samir Patel, MD

8:35

Discussion of above 2 papers

8:39

**Ocular Outcomes After Treatment of Cytomegalovirus (CMV) Retinitis Using Adoptive Immunotherapy with CMV-specific Cytotoxic T-lymphocytes**

Mrinali Gupta, MD

8:45

Discussion

8:48

**Long-Term Outcomes and Risk Factors for Severe Vision Loss in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)**

Timothy Boyce, MD

8:54

Discussion

8:57

**Optical Coherence Tomography of Anatomic and Temporal Biomarkers in Uveitic Macular Edema**

Thomas Albini, MD

9:01

**Safety and Visual Function of Suprachoroidal CLS-TA Versus Real World Rescue Therapies for Macular Edema Associated with Noninfectious Uveitis: A Post-hoc Analysis**

Pouya Dayani, MD

9:05

Discussion of above 2 papers

9:09

**Towards an Imaging-Based Definition of Autoimmune Retinopathy**

Nieraj Jain, MD

9:15

Discussion

9:18

**Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase (ERK)-inhibitor Associated Retinopathy**

Jasmine Francis, MD, FACS

9:24

Discussion
9:27 Practice Patterns and Outcomes of Intravitreal Injections for the Treatment of Retinopathy of Prematurity — A Multicenter Study
Nimesh Patel, BS, MD

9:32 Geographic Access Disparities to Clinical Trials in Retinopathy of Prematurity in the United States
Yoshihiro Yonekawa, MD

9:37 Modeling Absolute Retinal Zone Size in Neonates as a Function of Gestational Age
Darius Moshfeghi, MD

9:42 Discussion of above 3 papers

9:48 Failures of Prophylaxis for Stickler Syndrome
Michael Shapiro, MD

9:53 am Extended Vitreous Base Laser in Stickler Syndrome
Michael Blair, MD

9:58 Discussion of above 2 papers

10:02 REFRESHMENT BREAK/EXHIBITS

10:32 Exploring Ang-2 Signaling in Vascular Stability in Patients with DME Receiving Faricimab in Phase 2 and Phase 3 Trials
Caroline Baumal, MD

10:38 Discussion

10:41 Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results from the Phase 3 YOSEMITE and RHINE Trials
David Eichenbaum, MD

10:47 Discussion

10:50 Dexamethasone Implant Appears to Slow Diabetic Retinopathy Progression: A Retrospective Analysis of the MEAD Study
Kevin Blinder, MD

10:54 Anatomic Evidence of Effectiveness in US Clinical Practice After Initiating Dexamethasone Implant in DME Eyes with Suboptimal Response to Anti-VEGF Therapy: An Analysis of the Vestrum EMR database
Yasha Modi, MD

10:58 Discussion of above 2 papers

11:02 Conversion Equations for Central Subfield Thickness Measurements Between Optical Coherence Tomography Machines in Eyes with Diabetic Macular Edema
Jennifer Sun, MD

11:06 Discussion

11:08 Long-Term Visual Outcomes and Morphologic Biomarkers of Vision Loss in Eyes with Diabetic Macular Edema Treated with Anti-VEGF Therapy
Francesco Bandello, MD, FEBO

11:12 Discussion

11:20 Intra-arterial tPA for Central Retinal Artery Occlusion and Rapid Point of Care Diagnosis
Gareth Lema, MD, PhD

11:26 Discussion

11:29 Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection Baseline BCVA on Outcomes in CRVO: Post-hoc Analysis of the COPERNICUS and GALILEO Trials
David Boyer, MD

11:33 Discussion

11:35 am Safety of Suprachoroidal Injection Procedure via Microinjector Across Three Retinal Disorders
Matthew MacCumber, MD, PhD

11:39 Discussion

11:41 Simultaneous Release of Aflibercept and Dexamethasone from a Biodegradable Ocular Drug Delivery System
Jennifer Kang-Mieler, PhD

11:46 Discussion

11:48 ADJOURN